Keyword: Vertex Pharmaceuticals
After 15 years at Vertex Pharmaceuticals, Patricia Hurter was ready for retirement. She ended up the CEO of Lyndra Therapeutics.
We caught up with four women who had moved up the ranks in biopharma and are leading companies in their first CEO role.
With its five-months-early FDA approval for Trikafta, Vertex ushered in the triple combo era in cystic fibrosis—and majorly expanded its treatable population in the process.
The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.
Carmen Bozic, M.D., Vertex's new head of global medicines development and medical affairs, will take over the CMO post April 1.
Looking to harness the body’s protein degradation processes, Kymera has raised more than $150 million for its pipeline of small molecules, led by a program targeting IRAK4, a protein involved in disease-signaling pathways.
Vertex Pharmaceuticals is jumping into diabetes with a $950 million acquisition of Semma Therapeutics and its stem cell-based diabetes treatments.
Though Editas and Allergan are not the first to test a CRISPR-based medicine in humans, their treatment is the first that edits DNA within the body.
Vertex taps CMO Kewalramani as newest CEO; Verb Surgical brings SurgiQuest founder on board; Disarm names Enzyvant head Shih to leadership role.
The question over who is really responsible for the costly creation of drugs has arisen in the U.K.
